Alterity Therapeutics Limited (ATHE)Healthcare | Biotechnology | Melbourne, Australia | NasdaqCM
2.58 USD
-0.11
(-4.089%) ⇩
(Oct. 16, 2026, 11:22 a.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 2:24 a.m. EDT
The immediate outlook is clouded by severe technical weakness and deteriorating fundamentals. Despite a massive 235% surge last year, the stock has since collapsed, trading well below its 50-day and 200-day moving averages, which signals a loss of momentum and a failed recovery attempt. The recent price action shows a distinct downtrend, closing lower over the past two weeks, confirming that the previous rally was not sustainable. Fundamentally, the company is in distress with negative revenue growth of nearly 80%, significant operating losses, and negative free cash flow. While the balance sheet remains robust due to substantial cash reserves relative to debt, the business model is currently failing to generate top-line growth or profitability. There is no dividend to provide income, and the lack of analyst coverage suggests limited institutional interest. The recent news regarding clinical trials offers a potential catalyst, but without immediate proof of efficacy or commercialization, the risk-reward profile remains skewed toward further downside in the near term. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.198624 |
| AutoARIMA | 0.202273 |
| MSTL | 0.203492 |
| AutoETS | 0.205887 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 125.87 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.196 |
| Excess Kurtosis | -0.69 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.453 |
| Revenue per Share | 0.204 |
| Market Cap | 46,977,588 |
| Forward P/E | -2.69 |
| Beta | -0.01 |
| Website | https://alteritytherapeutics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.44376278 |
| Address1 | 500 Collins Street |
| Address2 | Level 15 |
| All Time High | 797.4 |
| All Time Low | 1.0 |
| Ask | 4.56 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 34,130 |
| Average Daily Volume3 Month | 17,920 |
| Average Volume | 17,920 |
| Average Volume10Days | 34,130 |
| Beta | -0.005 |
| Bid | 3.45 |
| Bid Size | 1 |
| Book Value | 1.6424487 |
| City | Melbourne |
| Compensation As Of Epoch Date | 1,798,675,200 |
| Country | Australia |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.58 |
| Current Ratio | 14.52 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 2.955 |
| Day Low | 2.35 |
| Debt To Equity | 0.453 |
| Display Name | Alterity Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,754,654,400 |
| Earnings Timestamp Start | 1,754,305,140 |
| Ebitda | -25,090,684 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.494 |
| Enterprise To Revenue | 3.436 |
| Enterprise Value | 12,402,265 |
| Eps Current Year | -0.76533 |
| Eps Forward | -0.95767 |
| Eps Trailing Twelve Months | -0.9 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 61 03 9349 4906 |
| Fifty Day Average | 4.0194 |
| Fifty Day Average Change | -1.4394002 |
| Fifty Day Average Change Percent | -0.3581132 |
| Fifty Two Week Change Percent | -44.376278 |
| Fifty Two Week High | 5.89 |
| Fifty Two Week High Change | -3.31 |
| Fifty Two Week High Change Percent | -0.56196946 |
| Fifty Two Week Low | 2.35 |
| Fifty Two Week Low Change | 0.23000002 |
| Fifty Two Week Low Change Percent | 0.097872354 |
| Fifty Two Week Range | 2.35 - 5.89 |
| Financial Currency | AUD |
| First Trade Date Milliseconds | 1,064,842,200,000 |
| Float Shares | 14,426,854 |
| Forward Eps | -0.95767 |
| Forward P E | -2.6940386 |
| Free Cashflow | -14,740,514 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 11 |
| Fullday Change | -0.11000013 |
| Fullday Change Percent | -4.0892243 |
| Fullday Price | 2.58 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.92721003 |
| Gross Profits | 3,347,238 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.02062 |
| Implied Shares Outstanding | 18,208,368 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,782,777,600 |
| Last Split Date | 1,673,222,400 |
| Last Split Factor | 1:10 |
| Long Business Summary | Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia. |
| Long Name | Alterity Therapeutics Limited |
| Market | us_market |
| Market Cap | 46,977,588 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_2383747 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -23,400,948 |
| Next Fiscal Year End | 1,814,313,600 |
| Non Diluted Market Cap | 66,819,034 |
| Number Of Analyst Opinions | 4 |
| Open | 2.56 |
| Operating Cashflow | -22,523,332 |
| Operating Margins | -18.16157 |
| Phone | 61 3 9349 4906 |
| Previous Close | 2.69 |
| Price Eps Current Year | -3.3710947 |
| Price Hint | 4 |
| Price To Book | 1.5708253 |
| Price To Sales Trailing12 Months | 13.013124 |
| Profit Margins | 0.0 |
| Quick Ratio | 14.263 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.11000013 |
| Regular Market Change Percent | -4.0892243 |
| Regular Market Day High | 2.955 |
| Regular Market Day Low | 2.35 |
| Regular Market Day Range | 2.35 - 2.955 |
| Regular Market Open | 2.56 |
| Regular Market Previous Close | 2.69 |
| Regular Market Price | 2.58 |
| Regular Market Time | 1,792,164,145 |
| Regular Market Volume | 37,493 |
| Return On Assets | -0.34078 |
| Return On Equity | -0.54978 |
| Revenue Growth | -0.79 |
| Revenue Per Share | 0.204 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 18,208,368 |
| Shares Percent Shares Out | 0.0014 |
| Shares Short | 26,107 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 31,452 |
| Short Name | Alterity Therapeutics Limited |
| Short Percent Of Float | 0.0014 |
| Short Ratio | 1.68 |
| Source Interval | 15 |
| State | VIC |
| Symbol | ATHE |
| Target High Price | 16.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 13.25 |
| Target Median Price | 13.5 |
| Total Cash | 37,317,960 |
| Total Cash Per Share | 2.049 |
| Total Debt | 193,465 |
| Total Revenue | 3,610,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.9 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.03595 |
| Two Hundred Day Average Change | -1.4559503 |
| Two Hundred Day Average Change Percent | -0.36074534 |
| Type Disp | Equity |
| Volume | 37,493 |
| Website | https://alteritytherapeutics.com |
| Zip | 3,000 |